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Spinal Muscular Atrophy (SMA) is caused by deletions or mutations in the Survival Motor Neuron 1 (SMN1) gene. The
second gene copy, SMN2, produces some, but not enough, functional SMN protein. SMN is essential to assemble small
nuclear ribonucleoproteins (snRNPs) that form the spliceosome. However, it is not clear whether SMA is caused by
defects in this function that could lead to splicing changes in all tissues, or by the impairment of an additional, less well
characterized, but motoneuron-speciﬁc SMN function. We addressed the ﬁrst possibility by exon junction microarray
analysis of motoneurons (MNs) isolated by laser capture microdissection from a severe SMA mouse model. This
revealed changes in multiple U2-dependent splicing events. Moreover, splicing appeared to be more strongly affected
in MNs than in other cells. By testing mutiple genes in a model of progressive SMN depletion in NB2a neuroblastoma
cells, we obtained evidence that U2-dependent splicing changes occur earlier than U12-dependent ones. As several of
these changes affect genes coding for splicing regulators, this may acerbate the splicing response induced by low SMN
levels and induce secondary waves of splicing alterations.
Introduction
Spinal Muscular Atrophy (SMA) is a hereditary disease that
leads to degeneration of motoneurons (MNs) in the spinal cord
and consequently to muscle atrophy. Its occurrence rate and car-
rier frequency have been estimated at »1/10’000 and »1/50,
respectively, with some differences due to ethnic origin.1-4 SMA
is considered rare, but it is nevertheless the most frequent inher-
ited disorder leading to death in infants.
The disease-causing gene Survival Motor Neuron (SMN) is
duplicated on human chromosome 5.5 In SMA patients, a com-
plete loss of function of SMN1 is responsible for »95% of cases,
but at least one copy of SMN2 remains. A crucial difference
between SMN1 and SMN2 is the nucleotide at position 6 of
exon 7: a cytosine in SMN1 is part of a SRSF1-dependent exonic
splicing enhancer (ESE) that favors exon 7 inclusion; in contrast,
a thymidine in SMN2 interrupts this ESE and creates an
hnRNPA1-dependent splicing silencer resulting in predominant
exon 7 skipping.6-10 As a consequence, SMA is due to low levels
of full-length, functional SMN protein.
The SMN protein has one well-established function and sev-
eral additional proposed ones. Its biochemically best character-
ized function is to mediate, in complex with several other
proteins called Gemins, the assembly of small nuclear ribonu-
cleoproteins (snRNPs) involved in splicing and other RNA proc-
essing reactions (reviewed in11). The snRNPs which get
assembled by the SMN complex are the major spliceosome com-
ponents U1, U2, and U4, the minor spliceosomal snRNPs U11,
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U12 and U4atac, the U5 snRNP common to both types of spli-
ceosomes, and the U7 snRNP involved in 3’ end processing of
histone mRNAs. Whether SMN also plays a role in the assembly
of the Lsm protein-containing snRNPs U6 and U6atac has not
been established. Because the SMN-dependent snRNP assembly
is essential to maintain splicing in all cells, it is not immediately
evident how reduced SMN levels could lead to a MN-specific
disease through this function.12,13 However, SMN levels might
be more limiting in MNs than other cells, either because the mis-
splicing of SMN2 may be more pronounced14 or because of a
higher demand for snRNPs. Another possibility is that the mis-
splicing ensuing from reduced snRNP assembly may be exclu-
sively detrimental for MNs, because the products of certain genes
misexpressed in these cells happen to be essential for MN func-
tion and survival. Variants of this hypothesis propose that SMN
may act in minor tri-snRNP assembly15 or intranuclear snRNP
mobility16 and that alterations in these functions may cause splic-
ing defects. In support of this snRNP-centered hypothesis for
SMA pathogenesis, the snRNP assembly activity of SMN point
mutations has been found to correlate with disease severity in
transgenic mouse models.17,18 Moreover, Fischer and co-workers
working with zebrafish embryos have been able to counteract MN
growth defects induced by antisense oligonucleotide-mediated
SMN depletion by injecting snRNPs isolated from HeLa cells.19
Regarding additional, possibly MN-specific functions, there are
indications that SMN might be involved in the assembly of other
ribonucleoprotein particles such as snoRNPs,20 telomerase,21 or
the signal recognition particle.22 Moreover, in cultured neuronal
cells, SMN has been localized in axonal outgrowths together with
other factors of RNA metabolism such as Gemins 2 and 3,
hnRNP Q and R, HuD, or FMRP, suggesting that it might play
a role in axonal mRNA transport (reviewed in13). SMN-containing
granules have been described to be associated with the COP1 com-
plex involved in vesicular transport23 and with the Golgi net-
work.24 Furthermore, SMN has been proposed to have an anti-
apoptotic role in neurons,25-28 and to be involved in transcription
regulation29 or neuronal migration and differentiation.30-32 In Dro-
sophila, SMN has also been suggested to play a role in stem cell
division, proliferation and differentiation.33
On a cellular and organismal level, it is interesting to note that
the first SMA symptoms, at least in mouse SMA models, do not
appear to affect the MN cell bodies, but rather the periphery, i.e.
the neuromuscular junctions (NMJ).34-36 NMJ abnormalities
have also been demonstrated in several muscles of 14 week-old
human fetuses with SMA type I.37
The role of snRNP assembly defects in SMA has been mostly
addressed by measuring snRNA levels and by assessing global
mRNA splicing. Two studies showed that a reduction of SMN leads
to an imbalance of snRNPs; in particular snRNPs of the minor
(U12-dependent) spliceosome seemed to be affected.35,36 In one
microarray study carried out with whole spinal cord of advanced stage
SMA mice, massive splicing changes were observed,38 but other
microarray studies in presymptomatic mice39,40 or in a mild SMA
model41 failed to reveal widespread splicing changes. One particular
U12-dependent splicing event has recently been highlighted as a pos-
sible cause contributing to SMA pathology: missplicing of a U12
intron in the geneTmem41b (known as Stasimon inDrosophila) leads
to a reduction of the Tmem41b protein which seems to be important
for maintaining motor circuit function.42
Based on the above, we considered it worth to carry out
another analysis of SMA-induced splicing defects because of cer-
tain novel features that we designed into our project. In particu-
lar, we isolated MNs by laser capture microdissection (LCM)
which means that our samples were highly enriched in the cells
relevant for SMA. Apart from a recent study which was published
while we were writing this manuscript,43 our study is so far the
only large-scale analysis carried out with LCM-isolated MNs
from SMA mice. As another modification compared to previous
studies, we have used exon junction microarrays that allow for a
very detailed analysis of alternative splicing events. Finally, we
had the unique possibility to compare not only healthy mice and
SMA mice, but also SMA/U7 mice in which the disease is pre-
vented or partly corrected.44
This analysis revealed a considerable number of strong
changes in U2-dependent splicing events. By comparison with
other global splicing studies carried out with whole spinal cord
RNAs, our results suggest that splicing alterations may be more
abundant and occur earlier in MNs than in other parts of the spi-
nal cord. Changes in U12-dependent splicing events were not
detected by the microarrays, but some could be identified by RT-
PCR analysis of LCM-isolated MN RNA. However, in a model
of progressive SMN depletion in NB2a neuroblastoma cells,
changes in U2-dependent splicing seemed to occur earlier and
affect more genes than alterations in U12-dependent splicing.
Furthermore, strong reductions of multiple U snRNAs occurred
only after prolonged SMN depletion in this model, and snRNAs
of the minor spliceosome did not appear to be preferentially
reduced. Importantly, we also found multiple genes encoding splic-
ing regulators and modifiers of such regulators to be affected at the
splicing level. This suggests that low levels of SMN can trigger a
cascade of splicing alterations in which the affected splicing regula-
tors alter the splicing of an ever growing number of genes.
Results
Microarray analysis reveals splicing changes in motoneurons
from the severe SMA mouse model
To study splicing defects in SMA, we analyzed RNA from
MNs of lumbar spinal cord segments of 3–4 day-old mice (post-
natal day 3, P3) of the severe SMA mouse model.45 In this model,
2 allelic copies of human SMN2 allow survival of mouse Smn
knock-out animals until 5–7 d after birth. At 3–4 days, the num-
bers and morphologic appearance of MNs are still normal. First
pathological signs can be seen in NMJs of the diaphragm and
intercostal muscles that are innervated by the cervical and thoracic
segments of the spinal cord, respectively.46,47 However, calf
muscles which are innervated from lumbar segments appear nor-
mal. It has not been thoroughly investigated whether more proxi-
mal hindlimb muscles or muscles from the lower trunk that also
get innervated from lumbar spinal cord segments may show some
pathology in this model and at this age. Whichever is the case, our
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samples can be said to represent an early,
but symptomatic stage of the disease.
More specifically, MNs were isolated
by LCM from lumbar spinal cord sec-
tions of 4 animals each of the following
genotypes: mSmn C/¡, hSMN2 C/C
(heterozygote/hz); mSmn ¡/¡, hSMN2
C/C (SMA mice); and mSmn ¡/¡,
hSMN2 C/C carrying several copies of
a therapeutic U7 gene known to correct
the SMA phenotype (SMA/U7
mice;44). RNA isolated from these
MNs was amplified and reverse tran-
scribed, and the cDNAs were hybrid-
ized to Affymetrix exon junction arrays.
For the evaluation, the samples were
subjected to 4 pairwise comparisons
(Fig. 1A). The first 3 SMA mice were
compared to the first 3 hz mice as well
as to the first 3 SMA/U7 mice. Simi-
larly, the SMA mice 2–4 were com-
pared to the mice 2–4 of the other 2
groups. The reason for this procedure
was that the ASPIRE software48 used
for the analysis allowed for only 3 arrays
in each pair to be compared. This gave
us 2 separate values for each compari-
son, even though these were not
completely independent, because 2 of
the mice from each group were shared.
The values initially analyzed were dI
(the change in% inclusion of the partic-
ular probe) and dIrank (a statistical
ranking of the splicing change). Accord-
ing to the experience of the Ule lab and
members of the EURASNET consor-
tium who worked with these arrays pre-
viously, dIrank values >1 or <¡1
should give a RT-PCR validation rate
of »85% when tested in the same bio-
logical system.48 We then calculated
mean values for these 2 parameters
from the 4 pairwise comparisons
described above. To facilitate the rank-
ing and grouping of these values, we
additionally gave positive and negative
score points if the mean dI of a compar-
ison was equal or larger than 25% in
positive or negative direction, or if the
mean dIrank was  0.75 or  ¡0.75.
Thus, any given probe could reach a
sumscore value of maximally plus or
minus 8 points from all 4 comparisons.
Of the 320875 probes present on the
microarrays, 27’729 were informative.
Figure 1. Summary of microarray data. (A) Schematic representation of microarray comparisons.
SMA mice 1–3 were compared to heterozygous (hz) mice 1–3 and to SMA/U7 mice 1–3. Similarly, SMA
mice 2–4 were compared to the mice 2–4 of the other 2 groups. In SMA/U7 mice, SMN2mRNA splicing
and the SMA phenotype are partly corrected by the expression of a therapeutic U7 snRNA trans-
-gene44. (B) Summary of relative probe inclusion (I) values in hz and SMA mice as well as in SMA/U7
mice. Error bars represent standard deviations. P values for 2-sided Student T test: strongly excluded
(N D 229), SMA vs. hz, 2.2 x 10–154, SMA vs. SMA/U7, 1.6 x 10–90, SMA/U7 vs. hz, 0.068; strongly
included (N D 248), SMA vs. hz, 3.4 x 10–70, SMA vs. SMA/U7, 2.2 x 10–54, SMA/U7 vs. hz, 0.077. (C)
Gene ontology analysis of molecular functions (performed at www.pantherdb.org) of genes showing
strong splicing changes (see Tab3 of Supplementary File 1 for analyses of further categories).
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Probes with absolute sumscore values 3 and absolute average
dIrank 0.75 were placed in groups of strong positive and strong
negative splicing changes. From these initial groups, we manually
eliminated some probes with small differences between SMA and
wt animals or with contradictory results. This resulted in 229
and 248 probes with strongly positive or negative splicing
changes, respectively (Table 1). The vast majority (82%) were
predicted to be more strongly included or skipped cassette exons.
The remaining events were equally distributed among alternative
50 or 30 exons and intron retention events. All changes affected
major, U2-dependent exons. Full lists of these strong positive
and strong negative events are presented in Tabs 1 and 2, respec-
tively, of the Supplementary File 1. A statistical comparison of
the mean dI values of these 2 groups to the entire library is shown
in Figure 1B. The relatively high standard deviations reflect the
fact that the mean dI values cover a broad range between about
60 and 10% probe inclusion or exclusion (Table 1). Importantly,
however, the average dI values of SMA animals in both groups
differ very significantly from those of the healthy heterozygous
(hz) or U7/SMA mice. In contrast the values of the SMA/U7
and hz mice show no significant difference. This indicates that
the splicing changes detected by the microarray are indeed caused
by the SMA genotype and do not occur or are strongly reduced
in SMA/U7 mice. In contrast, averaged over the entire set of
27’729 informative probes, there was almost no change between
the different mouse genotypes (Average dI and dIrank of 0.162
and 0.005, respectively).
We then performed a gene ontology analysis at the PAN-
THER website (www.pantherdb.org) for the entire set of genes
showing strong splicing changes. Of 353 genes that were properly
identified by the software, »70% of 406 hits fell into the follow-
ing 3 molcular function categories: binding (31.8%, mostly
nucleic acid-binding), catalytic activity (30.8%) and transcription
factor activity (8.9%) (Fig. 1C). The three most prominent iden-
tified biological processes (total number of hits: 607) were: meta-
bolic (29.5%, mostly nucleobase and protein metabolism),
cellular (21.3%, mostly cell communication and cell cycle) and
localization (9.9%, mostly vesicle-mediated and protein trans-
port) (see Tab 3 of the Supplementary File 1 for further details).
Finally, the microarray analysis also revealed expression
changes of certain RNAs (see Tabs 4 and 5 of Supplementary
File 1), but many of these transcripts were not annotated, and
the splicing alterations appeared more prevalent.
Candidate validations in SMA mouse motoneurons
and SMN-depleted NB2a neuroblastoma cells
We then proceeded to validate some of the splicing changes
revealed by the microarray analysis. Initially, we tried to do this
by performing RT-PCR of whole spinal cord RNA from SMA
and hz mice at P3. However, none of the genes tested by this
approach showed any splicing changes (for an example see Fig. 3
below). The failure to detect splicing differences by this approach
may have been due to the fact that MNs represent only a small
fraction of all spinal cord cells. Thus changes in MNs may have
been masked by a constant or inverse splicing behavior in the
other cells. To circumvent this problem, we then used RNA iso-
lated from microdissected lumbar spinal cord MNs (i.e., identical
material as used for the microarrays). However, because of the
methodological difficulty and the low yield of material, we were
able to validate only a few selected events by this method.
As a third strategy, we used RNA from NB2a mouse neuro-
blastoma cells that were partly depleted of SMN by transient
RNA interference. This cell culture model allowed us to analyze
more splicing events and to obtain a larger picture of the order of
events (see below). In this model, the level of mouse SMN
mRNA was reduced to »15% after 3 d and to »5% after 5 d of
SMN depletion, and the SMN protein was similarly reduced, to
14% and 9%, respectively (Fig. 2). Thus the depletion was pro-
gressive over this time period but somewhat less extensive than in
P3 severe SMA mice, where SMN transcripts were barely detect-
able by conventional RT-PCR (see Fig. 3 below). As a compari-
son for protein levels, we previously found SMN protein levels in
spinal cords of P3 severe SMA mice to be less than 10% of wild-
type levels.44 Usually, the NB2a cells were still proliferating until
3 d post-transfection, albeit at a reduced rate compared with con-
trol cells depleted of T cell receptor b (TcRb). At this time point,
proliferation ceased and cells started to die so that cell numbers
were usually reduced 2- to 4-fold by 5 d (data not shown). Based
on metabolic measurements (resazurin assays), the metabolic
activity of cells at 3 d of MN depletion was reduced to »60% of
control cells, while residual cells at 5 d of depletion showed only
»35% metabolic activity (Fig. S1 of Supplementary File 2).
Table 1. Statistics of microarray data
dI dI rank sumscore
number mean max min mean max min mean max min
total probes 32875
informative probes 27729 0.162 0.005
negative strong 229 -26.895 -66.125 -10.785 -1.165 -4.063 -0.750 -4.594 -8 -3
positive strong 248 27.209 56.805 11.030 1.235 6.770 0.750 4.810 8 3
dI: difference in % probe inclusion of SMA mice compared to heterozygous and SMA/U7 mice
dI rank: statistical ranking of splicing changes; dIrank values>1 or <¡1 should give a RT-PCR validation rate of of »85%48
sumscore: score points were given when the absolute dI value of a comparison was  25% or when the absolute dIrank was  0.75; as each probe was com-
pared twice between SMA and wt and twice between SMA and SMA/U7, and the score points given had positive or negative values depending
on the direction of the splicing change, any given probe could reach a sumscore value betweenC8 and ¡8 points from all four comparisons.
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In the NB2a cell model, we analyzed 92 candidates from the
list of strongly altered splicing events identified in the MN
microarray analysis. We preferentially chose strongly altered
events as predicted by the microarrays or events in genes consid-
ered to be important for gene regulation or the development and
functions of the nervous system. When the cells had been
depleted of SMN for 3 days, 16 of these events showed strong
changes and 6 showed mild alterations, amounting to »24% of
all analyzed events (Tables 2a and 2b). The other events either
yielded unclear results, showed no change, or the transcripts were
not detectable in NB2a cells. Interestingly, 9 of the 22 affected
events changed in the opposite direction from the one predicted
by the microarrays. Nevertheless, the majority of changes (13)
was in the same direction as indicated by the microarrays.
Moreover, 17 splicing events were analyzed with RNA sam-
ples from microdissected MNs. As the laser capture microdissec-
tion was very labor-intensive and yielded only small amounts of
RNA, we restricted this type of assay to genes for which we had
previously detected splicing changes in NB2a cells or to events
that were ranked as most highly altered in the microarray results.
Among these, we could detect changes in 7 splicing events
(Tables 2a and 2b). For six of these, the splicing change was as
predicted by the microarrays. Only for one gene (A2bp1/Rbfox,
see below), the change was in the opposite direction compared to
the microarray results.
Examples of these analyses are shown in Figure 3. The tran-
scription factor E2F6 may play a role in the silencing of target
genes and in controlling the cell cycle.49 The microarray indi-
cated an increased use of a 66 nucleotide exon (termed here 1a)
that leads to truncation of the open reading frame due to an in-
frame stop codon. In isolated MNs, only the upper band corre-
sponding to the inclusion of the additional exon could be
detected by RT-PCR, and its amounts seemed to be increased in
SMA mice (Fig. 3, first row). The splicing of E2f6 was also ana-
lyzed in RNAs from whole spinal cord and heart. In these sam-
ples, both products were detected, but their ratio did not change.
As previously mentioned, also other genes, when tested in whole
spinal cord RNA, did not show any of the changes indicated by
the MN microarrays. However, in NB2a cells depleted of SMN,
E2f6 showed the increased use of the alternative exon predicted
by the microarrays.
Aftiphilin (Aftph) is a component of the clathrin machinery in
neurons that co-localizes at synapses with synaptophysin and
with the AP-1/AP-2 clathrin adaptor complexes.50,51 In agree-
ment with our microarray data, the use of exon 8 (81 nucleotides,
open reading frame retained) could be shown by RT-PCR to
increase in MNs of SMA mice (Fig. 3, second row). However
Aftph is one of several genes that showed an inverse splicing
change in NB2a cells compared to MNs. The effects of these
changes on the protein are unknown, as no functional domains
have been characterized.
The third example is the gene encoding the protein "RGD
motif, leucine rich repeats, tropomodulin domain and proline-
rich containing" (Rltpr) also known as "Leucine-rich repeat pro-
tein 16c" (Lrrrc16c). This gene produces a transcript of 37 exons
encoding leucine-rich repeats in the N-terminal half, a motif
interacting with the actin filament capping protein and a C-ter-
minal proline-rich region. The protein and its different paralogs
may be involved in actin filament uncapping.52-54 Moreover
Rltpr was recently shown to play a role in CD28 co-stimulation
of T-cells.55 The alternative exon (termed here 35a) adds 27
amino acids to the proline-rich region. The use of this exon was
Figure 2. Quantitation of residual SMN expression in SMN-depleted
NB2a cells. Mouse NB2a neuroblastoma cells were depleted of SMN for
3 or 5 d (designed below as 3S and 5S, respectively). As control, the cells
were similarly depleted of TCRb which should not be expressed in these
cells (3T and 5T). (A) Transcript levels were analyzed by RT-qPCR using
5.8S rRNA as a reference. Error bars represent standard deviations. P val-
ues for 2-sided Student T test (N D 8): 3S vs. 3T, 1.1 x 10–13, 5S vs. 5T,
8.4 x 10–20, 3S vs. 5S, 0.013. (B, C) For the analysis of protein levels, whole
cell extracts were analyzed by Western blotting with antibodies detect-
ing mouse SMN and a-tubulin. Images were analyzed and bands quanti-
tated as described in Materials and Methods. A representative Western
blot is shown in C, and the compiled results of 6 experiments are sum-
marised in B. P values for 2-sided Student T test: 3S vs. 3T, 5.6 x 10–14, 5S
vs. 5T, 2.6 x 10–12, 3S vs. 5S, 0.081.
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reduced in MNs from SMA mice as predicted by the microarrays
as well as in SMN-depleted NB2a cells (Fig. 3, third row).
Finally, we show the results obtained for A2bp1/Rbfox1. This
"Fox1 homolog A," also known as "ataxin 2-binding protein 1"
or "hexaribonucleotide-binding protein 1" contains an RNA rec-
ognition motif56 and may thus be involved in neuronal splicing
regulation, similar to Fox1. However it also binds to the C-termi-
nus of ataxin-2 and co-localizes with ataxin-2 in the trans-Golgi
network.56 The microarrays had indicated a reduced use of an
alternative 5’ exon in SMA mice which could also be detected in
SMN-depleted NB2a cells (Fig.3, fourth row). However, A2bp1/
Rbfox1 is the only gene for which we observed an inverse splicing
change between RT-PCR and microarrays of isolated MN RNA.
Some, but not all, of these splicing changes became more
prominent as the SMN depletion progressed to 5 d As examples
for this type of behavior, RT-PCR analyses of Ewsr1 and Deaf1
are shown in Figure 4 (1st and 2nd row). Both of these gene
products are thought to be involved in the regulation of tran-
scription or RNA metabolism (Table 2a). Moreover, additional
splicing events began to be affected with longer, more extensive
SMN depletion, such as the
switch between 2 alternative
5’ exons in Sept9 (Fig. 4,
3rd row). Sept9 is a member
of the septin family involved
in cytokinesis and cell cycle
control,57 and certain muta-
tions in this gene can cause
the disease Hereditary Neu-
ralgic Amyotrophy.58
Changes in U12-
dependent splicing become
apparent after prolonged/
extensive SMN depletion
Interestingly, there were
no U12-dependent events
among the top-listed splic-
ing changes of our MN
microarray data. This find-
ing was unexpected, because
reductions in minor U
snRNAs17,38,42 and splicing
alterations in U12-introns42
had been described as one of
the hallmarks of SMA. Two
reasons might be responsible
for this apparent lack of
U12-dependent splicing
changes: first, U12-depen-
dent splicing events may be
underrepresented in the
microarrays; secondly, the
usual outcome of an
impaired U12-dependent
splicing event should be the
retention of the U12-intron; this may easily escape detection,
because intron-containing RNAs can be degraded rapidly, e.g.
through the mechanism of nonsense-mediated mRNA decay
(NMD).
Thus, we decided to analyze whether U12-introns do show
alterations in our NB2a SMN depletion model and whether these
alterations occur earlier or later than the changes seen in U2-
dependent events. For this analysis, we tested a certain number of
genes that had shown strong splicing changes in the microarrays
but which contained U12-introns elsewhere in the gene. Addi-
tionally, we analyzed the splicing of the U12-introns present in
Tmem41B and Zpr1, since the U12-intron of Tmem41b had
been indicated as a potential pathogenic factor for SMA,42 and
Zpr1 (also known as Znf259) had been suggested to modify
SMA.59
Interestingly, of 12 U12-dependent events that were detect-
able in NB2a cells, none showed changes at 3 d of SMN deple-
tion by conventional agarose gel analysis of RT-PCR products.
Only when the SMN depletion was prolonged to 5 days, we
could detect an increased retention of the U12-introns of Eed
Figure 3. Validation of splicing changes by RT-PCR. Analyses shown on the left were performed with cDNA from
spinal cord, heart and LCM-isolated motoneurons (MN) prepared from P3 SMA (3SMA) and heterozygous mice
(3 hz). Panels on the right show analyses of cDNA from mouse NB2a neuroblastoma cells that had been depleted of
SMN for 3 or 5 d (lanes labeled 3S and 5S, respectively). As control, the cells were similarly depleted of TCRb which
should not be expressed in these cells (3T and 5T). The splicing of the gene region of interest was analyzed by RT-
PCR with appropriate primers. Gene symbols are listed on the right; numbers in brackets represent the fold change
in probe inclusion (dI) as calculated from the microarray data (1 D equal inclusion). The central column indicates
the exons contained in the various amplicons; exons of interest are shown in bold and larger font size; alt 5’: alterna-
tive 5’ exon; a: alternative exon. The lower sections show RT-PCR products of endogenous mouse SMN RNA to illus-
trate the extent of depletion and of 5.8S rRNA used as loading control.
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and Taf2 (Fig. 5A). For Ap4m1 and Tmem41b, the levels of nor-
mal transcripts were reduced at 5 d (Fig. 5B) which may have
been due to NMD triggered by aberrant splicing, as reported in
the work of Lotti et al. 2012.42 A marginal reduction of tran-
script levels was also seen for Trit1 (data not shown). For the
U12-introns in E2f6 (Fig. 5A) and 6 other genes (Eftud1,
Mbtps2, Slc25a14, Tnpo2, Usp14, Zfp259; data not shown), there
was no clear indication of an intron retention, and the transcript
levels appeared to remain unaffected.
The RT-PCR method used in the experiments described so
far is useful to detect splicing changes, when 2 or more splicing
products are produced and one finds changing ratios between
these products. For a given sample, these ratios are robust over a
wide range of RNA or cDNA input amounts and replication
cycles (Ref.60; own unpublished results). However, when a single
band is observed in varying quantities, this method is not reliable,
as differences may disappear or be underestimated when the
PCRs reach saturation. For this reason, the Ap4m1 and
Tmem41b) genes whose transcripts had shown reductions of a
single band were reanalysed by quantitative (real-time) PCR of
the cDNAs. This revealed that the level of Ap4m1 mRNA was
reduced to 54% of the level of the control cells after 3 d of SMN
depletion and to 40% after 5 d (Fig. 5C). Similarly, the
Tmem41b level was reduced to 72% after 3 d and to 40% after 5
d of SMN depletion. However, the change of this gene at 3 d
was only slightly significant (p D 0 .041).
These results indicate that changes in U12-dependent splicing
events do occur in SMN-depleted NB2a cells but that they may
require a prolonged and/or stronger SMN reduction to become
detectable than U2-dependent events.
We then also tested the U12-exon containing Ap4m1 and
Tmem41b genes in LCM-isolated MNs of lumbar spinal cord.
Indeed we could observe a similar reduction of transcript levels
(Fig. 5D) as in the NB2a cells that had been depleted of SMN
for 5 d (Fig. 5C).
We also tried to quantitate U snRNA levels by RT-qPCR in
the SMN-depleted NB2a cells, in order to determine to what
extent the observed splicing changes might be due to reductions
in spliceosomal snRNP levels. However, as the results showed a
relatively large degree of variation between experiments, it was
difficult to draw strong conclusions. Nevertheless, these data
indicated that strong reductions in multiple U snRNAs only
become apparent after 5 d of SMN depletion, and that there is
no obvious difference in the reduction between U snRNAs of the
minor and major spliceosomes (Fig. S2 of Supplementary File 2).
Discussion
SMA-induced splicing alterations appear to be more
prevalent in motoneurons than in other neural tissues
This study was initiated to analyze one of the prevailing
hypotheses for SMA pathogenesis. As SMN plays a central role
in snRNP assembly,11 this hypothesis proposes that an assembly
defect could contribute to SMA pathogenesis in the sense that
reduced snRNP levels may cause splicing changes, some of which
may in turn affect vital functions in MNs.
Previous studies which addressed this point had analyzed
splicing and transcript levels in whole spinal cord, sometimes in
comparison with other tissues, from the severe40 or D738-40 SMA
mouse models and in one case also from a milder model.41 The
authors had used exon arrays which are somewhat less sensitive in
detecting alternative splicing events than the exon junction
microarrays used here. A consensus that could be derived from
these studies was that wide-spread splicing defects are a feature of
late symptomatic stages.38-40 In contrast, no or only few changes
were detected in pre-symptomatic or early symptomatic
stages39,40 or in the mildest analyzed SMA model.41
Our own study, as well as a recent paper43 which used next
generation sequencing for the analysis and that was published
while we were writing our manuscript, are the first ones that have
analyzed SMA-related splicing defects specifically in MNs.
Together, they reveal a different picture regarding the prevalence
of splicing changes in early phases of the disease. As discussed in
the initial results section, our own samples from lumbar MNs of
P3 mice can be regarded as early symptomatic. In the recent
study by Zhang et al., the transcriptome of MNs was analyzed at
a yet earlier stage.43 These authors also isolated MNs from the
lumbar region, but in P1 mice of the milder D7 model. As both
studies revealed a considerable number of splicing changes, it
appears that splicing may be affected in MNs more extensively
and at an earlier time point than in other cells of the spinal cord.
In agreement with this, we were not able to validate splicing
changes in whole spinal cord, but could do so for several genes in
cDNA from isolated MNs (Fig. 3). Similarly, Zhang et al. found
fewer and different splicing changes in the white matter than in
MNs of the same spinal cord sections.43 This early affection of
MN transcriptomes may be related to the finding that the skip-
ping of SMN2 exon 7 is also more pronounced in isolated MNs
than in surrounding spinal cord tissue.14
When we compared our microarray data to those of the other,
published studies,38,39,43 we could identify 30 cases in which the
same splicing event was changed or the change was at least likely
to have affected the same exon(s) in 2 or more analyses (Table 3).
Additionally, we found 14 matching genes for which we could
not identify unambiguously which exon(s) were affected
(Table S1 of Supplementary File 2) and 18 cases where the same
gene but different exons seemed to be affected (Table S2 of Sup-
plementary File 2). Note that, for the older exon array data, it is
often difficult to determine exactly which splicing event is
affected within a gene. For all but one of these studies, the certain
or likely exact matches represent a small fraction (1–7%) of all
identified splicing changes (Table 3). A further evaluation of the
data fromTable 3 revealed that the matches fall into 2 main clus-
ters (Table 4). One of these is represented by analyses of whole
spinal cord samples of D7 mice at P7, P11 and P13 with a
slightly less extensive overlap between P1 and P7 samples.38,39
The second cluster consists of the 2 studies on isolated MNs
from P3 mice of the severe model (our study) and D7 mice at
P1.43 This further underscores the notion that the transcriptomes
of MNs are different from those of the remaining spinal cord
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and that disease-induced splicing changes in MNs may be
obscured and escape detection when one looks at RNA from
whole spinal cord.
What is the importance of major and minor spliceosomes for
SMA?
An important discussion in the field concerns the relative con-
tributions of the 2 spliceosomal systems (U2 vs. U12) to SMA
pathogenesis. The idea that the minor spliceosome may be partic-
ularly important for SMA was put forth, because measurements
of U snRNA concentrations in cellular SMN depletion systems
and tissues of SMA mice had revealed a stronger reduction in
snRNAs of the U12-spliceosome.17,38,42
Contrasting with this notion, the transcriptome studies car-
ried out on different SMA models,38-41,43 including our own
study, have revealed numerous alterations in U2-dependent splic-
ing events, but none in U12-dependent events. As mentioned
previously, this may partly be due to a bias of the analytical sys-
tems. Deficiencies in U12-dependent splicing events are usually
manifested by intron retention or by a decrease in transcript lev-
els, because the intron-containing RNA variants are subject to
NMD. Such events might not be efficiently detected by any
method, be it exon or exon junction arrays or deep RNA
sequencing.
The experimental system of SMN-depleted NB2a cells which
we used for our validations helped to shed some light on this
question, as it allowed us to study splicing changes for a relatively
large set of genes. Most importantly, we could study the partial
SMN depletion while it progressed from an early, moderate to a
later, more extensive stage. Even though this system revealed a
number of differences compared to MNs, it has provided valu-
able information regarding the types of genes and introns affected
by SMN depletion.
Altogether, the NB2a system allowed us to detect more
than 22 changes in U2-dependent splicing events and 5
changes in U12-introns. After 3 d of SMN depletion, with
15–20% of SMN mRNA and protein remaining, all 22 U2-
dependent splicing events listed in Table 2 were altered. After
5 d of depletion, with an SMN reduction to 5–10%, several
of these changes became more pronounced, and additional
ones were detectable (Fig. 4). In contrast, the 5 observed
U12-dependent splicing changes (out of 12 testable events)
only became detectable by conventional RT-PCR at 5 d of
SMN depletion (Fig. 5). At 3 d of depletion, slight reduc-
tions in Ap4m1 and Tmem41b transcript levels could be mea-
sured by RT-qPCR, but, for Tmem41b, this reduction was
only marginally significant. Moreover, our qPCR measure-
ments of U snRNAs suggested that 5 d of SMN depletion in
NB2a cells are required for reductions in the levels of multi-
ple U snRNAs to become apparent (Fig. S2 of Supplemen-
tary File 2). However, these measurements did not provide
evidence for a preferential reduction of minor U snRNAs.
Taken together, our results therefore indicate that U2-depen-
dent splicing events are affected earlier than those of the
minor U12 spliceosome, at least in these NB2a cells.
Altogether, the U snRNA expression profile after 5 d of SMN
depletion looked more similar to those published for other
SMN-depleted cell models and SMA mouse tissues17,38,42 than
the one after 3 d of depletion. Multiple snRNAs were reduced,
although we cannot conclude from our data that this reduction
was stronger for snRNAs of the minor spliceosome compared to
those of the major one. It is possible that the extent to which dif-
ferent U snRNA levels are affected by a SMN deficiency may
vary between cellular systems (see Zhang et al. 200838 for exam-
ples). However, based on our data, we think that the situation
presented in previous studies, where most snRNAs showed a
reduction and some of the minor spliceosomal components were
most strongly affected,17,38,42 may reflect a point in time well
beyond the first occurrences of splicing defects.
Unfortunately it has not been tested, in any biological system,
when the first splicing changes occur in response to a reduced
SMN concentration and whether snRNP levels are significantly
reduced at this time point. In other words, it is still not clear
whether reduced snRNP assembly and reduced snRNP levels are
indeed the cause for these first splicing defects. As mentioned in
the Introduction, there is supporting evidence for this hypothesis.
Thus, the snRNP assembly activity of certain SMN point muta-
tions was found to correlate with disease severity in transgenic
mouse models.17,18 Moreover, MN growth defects induced in
zebrafish embryos by antisense oligonucleotide-mediated SMN
Figure 4. Prolonged SMN depletion in NB2a cells leads to more
extensive splicing alterations.Mouse NB2a cells were depleted of SMN
or TCRb for 3 and 5 days, and the splicing of the gene region of interest
was analyzed by RT-PCR as described in the legend of Figure 2. Numbers
in brackets below the gene symbols represent the fold change in probe
inclusion (dI) in SMA mice as calculated from the microarray data
(1 D equal inclusion). The exons contained in the ampliﬁed products are
indicated on the left with alternative exons shown in larger font size and
bold letters; alt 3’: alternative 3’ exon; a: alternative exon. For Sept9, the
assay detects a switch between the alternative 5’ exons of the transcripts
003 and 005.
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depletion could be prevented by injecting
snRNPs isolated from HeLa cells.19 Nev-
ertheless, a firm proof for the idea that
these splicing changes are indeed caused
by low snRNP levels in SMA patients or
in animal models which recapitulate the
human situation is missing. Thus one
should at least entertain the alternative
possibility that SMN may cause splicing
changes by a different mechanism, e.g.,
by affecting the metabolism or function
of other splicing factors such as SR and
hnRNP proteins which are key regulators
of alternative splicing.61,62
Genes affected and their possible
relationship to SMA pathogenesis
An important motivation for this
study was to gain insight into pathogenic
mechanisms leading to SMA through the
identification of genes whose splicing, or
more generally whose expression, is
altered. When we consider those genes
whose splicing changes were confirmed
in NB2a cells after 3 d of SMN depletion
(Table 2), these fall into 3 main func-
tional categories:
1. Cellular and developmental/neuronal
functions (Ank2, Aftph, Atp11c, Pkp4,
Rltpr, Sept9)
2. Transcription and growth control
(Deaf1, E2f6, Igf1, Mtf2, Pdcd2l,
Plag1, Src, Supt20h)
3. RNA metabolism, especially splicing
(Clk3, Cstf2, Ewsr1, Pum1, Rbfox1/
A2bp1, Scaf8/Rbm16, Tia1, Ythdc1)
Even though the selection of genes for our validation attempts
was somewhat biased, it is clear from this list that important
functions for any cell, and especially for neuronal cells, are
affected. A gene ontology analysis performed on the entire set of
strong splicing changes resulted in a similar picture (Tab 3 of the
Supplementary File 1; also see descriptions in first part of the
results). Moreover, one of the 3 splicing events which were
altered in our study and in MNs from D7 mice at P143 affects
the Gria2 gene that codes for the glutamate receptor 2, while the
other 2 concern genes for potential transcription/RNA processing
regulators (Scaf8/Rbm16 and Zfp821). The Gria2 transcripts are
known to be edited by adenine deamination, and a reduction of
this editing has been observed in the motoneuron disease Amyo-
trophic Lateral Sclerosis (ALS).63,64 This could be an interesting
cue to follow up in further studies.
Another one of the strongly regulated genes from our analysis
which was also identified in the whole spinal cord microarray
studies of Zhang et al. 200838 and B€aumer et al.39 is Uspl1. The
splicing of this gene has also been used as tracer in a recent study
on various stages of SMA mice.65 Its protein product, according
to the GeneCards database, is involved in the desumoylation of
proteins.
A few other genes for which we have detected splicing changes
in our MN microarrays may also contribute to the pathology of
the disease. For example, Eed, a member of the polycomb family
has been linked to deficient growth in stem cells.66 This could be
interesting, because a recent study in Drosophila has demon-
strated an influence of SMN on stem cell division, proliferation
and differentiation.33 Besides Eed, E2f6 is another putative mem-
ber of the polycomb complex. In the case of mouse MNs, E2f6
has a single transcript which codes for a truncated protein; it is
not known whether this could have any function. Furthermore,
the mouse Igf1 Ec splicing isoform was reduced at 3 d of SMN
depletion in NB2a cells. The Ec isoform has been reported to
play a neuro-protective role.67,68 Finally, as shown in Figure 5,
the transcripts coding for Tmem41b, a vital protein required for
maintaining the excitability of MNs,42,69 appear to be degraded
via NMD due to aberrant splicing of a U12-intron.
Figure 5. Evidence for U12 intron retention after prolonged SMN depletion in NB2a cells and
in SMA mouse motoneurons. (A) Examples showing intron retention in NB2a cells. The cells were
depleted of SMN or TCRb, and the splicing of the gene region of interest was analyzed by RT-PCR as
described in the legend of Figure 2. The labeling on the side of the gels indicates the exons partly
or fully ampliﬁed by this assay. Parts of retained U12 introns are indicated in bold and larger font
size. The U12 intron of interest is also mentioned between brackets following the gene symbol.
Note that the introns 4 of Eed and 12 of Taf2, but not the E2f6 intron 4, accumulate after 5 d of SMN
depletion. (B) Reduction of Ap4m1 and Tmem41b transcript levels after SMN depletion in NB2a cells.
The missing transcripts have most likely been degraded by nonsense-mediated mRNA decay
because of stop codons in the retained U12 intron. (C) RT-qPCR analysis of Ap4m1 and Tmem41b
transcript levels in SMN depleted NB2a cells. Error bars represent standard deviations. P values for 2-
sided Student T test (N D 4): Ap4m1, 3S vs. 3T, 1.6 x 10–5, 5S vs. 5T, 4.8 x 10–4, 3S vs. 5S, 0.19;
Tmem41b, 3S vs. 3T, 0.041, 5S vs. 5T, 0.023, 3S vs. 5S, 0.35. (D) Reduction of Ap4m1 and Tmem41b
transcript levels in LCM-isolated MNs from P3 SMA mice (3SMA) compared to heterozygous mice
(3hz). The experiments were performed with the same cDNA preparation for which results of other
genes including the SMN depletion control and the 5.8S rRNA loading control have been shown in
Figure 3.
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Despite the fact that the outcome of the splicing changes on
the encoded proteins has not been determined experimentally
and is sometimes difficult to predict based on gene structure, all
these and several of the other detected changes are potentially
very important for cell physiology and MN function. However,
it is difficult to identify which changes are primary ones, which
ones are particularly important for the development of the
disease state and which ones may simply be consequences of a
disturbed cell physiology without much significance for SMA
pathogenesis. Similar studies in earlier stages, i.e. in mouse
fetuses and perinatal stages, might help to shed some light on
these questions. However, the isolation of MNs in sufficient
quantity and quality will be technically more demanding for
such early stages.
Table 3. List of SMA-associated splicing changes identiﬁed in multiple studies.
A clustering of matches between this paper and Ref. 43 as well as between the studies of Refs 38 and 39 is indicated by stronger cell separations. EJA, exon
junction array; NGS, next generation sequencing; EA, exon array; @, full match, identical exons or splicing events affected; ?, possible match, usually affecting
adjacent exons that might be involved in the same splicing change.
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One advantage of our study, was that we could not only com-
pare SMA mice to healthy heterozygotes, but also to SMA/U7
mice in which a therapeutic U7 gene partly corrects SMN2 exon
7 splicing, and hence the SMA phenotype.44 The fact that, over-
all, the strongly altered splicing events were reversed in SMA/U7
mice indicates that most of them are indeed associated with the
SMA genotype. However, as the SMA/U7 mice inherited
the therapeutic U7 gene at conception, the U7 gene should have
caused a correction of all changes, regardless of whether they are
primary or secondary ones.
Altered expression of RNA processing regulators may
aggravate SMA-induced missplicing
One of the most important results of our study is that sev-
eral genes which showed splicing defects encode splicing and
3’ end processing factors or proteins that regulate the activity
of RNA processing factors (Clk3, Cstf2, Rbfox1/A2bp1, Scaf8/
Rbm16, Tia1, Ythdc1). Changes in this group of proteins
may therefore amplify the alternative splicing that is primarily
induced by low levels of SMN, or they may even feedback on
the splicing of the SMN2 gene. In particular, Tia1 has
recently been identified as a positive regulator of SMN2
exon7 splicing, so that a loss of Tia1 may contribute to a
negative feedback loop that reinforces exon7 skipping.70
Together with new evidence showing that the production of
functional SMN protein from SMN2 was lower in the MNs
of SMA mice than in other types of neurons of the spinal
cord,14 a dysregulation of Tia1 that has been shown to be
important for SMN exon 7 inclusion71 could at least partly
explain the extra vulnerability of MNs in SMA. Additionally,
Clk3 encodes a serine/threonine type protein kinase that reg-
ulates the intranuclear distribution of the SR family of splic-
ing factors.72 In principle, for each of these RNA processing
regulators, a change in its level or activity may induce a sec-
ondary wave of splicing defects which supersedes the one
caused by reduced SMN levels and altered snRNP assembly
or metabolism. In other words, we should perceive the mono-
genic defect of SMN to be the seed for a chain reaction of
splicing defects in SMA.
Materials and Methods
Plasmids and lentiviral constructs
Plasmids were cloned in E. coli strain XL10 Gold and ampli-
fied with chloramphenicol (final concentration 170mg/ml; added
during a second day of incubation).
Short hairpin (sh) RNA sequences targeting mouse SMN were
cloned as double-stranded oligonucleotides between BglII and
HindIII restriction sites, downstream of the H1 promoter, in a
pSUPERpuro73 derivative that contains a 1834bps stuffer frag-
ment (pSUPuro-sL) between these sites. Thus the stuffer frag-
ment was replaced by the shRNA sequence. Multiple shRNAs
were generated, but the one used for these experiments targets
the sequence GAAGTAAAGCACACAGCAA in exon 4 (i.e., the
fifth exon, as 2 exons are named 2a and 2b). As negative control,
a pSUPERpuro shRNA construct targeting T cell receptor b
(TcRb; which should not be expressed in the cells of interest)
was used.74 These pSUPERpuro vectors contain a puromycin
resistance gene that allows for rapid selection of transiently trans-
fected cells.
Cell culture and transient transfections
NB2a cells were maintained at 5% CO2 and 37
C in DMEM
supplemented with 10% fetal calf serum (FCS; Sigma), 100U/ml
penicillin, 100 mg/ml streptomycin and 2mM L-glutamine (all
from Amimed). For transient transfection, »2.5 £ 105 cells were
seeded per well (6-well plate) and incubated overnight. The
medium was replaced by serum- and antibiotics-free medium for
1 hour pre-transfection. Complexes of DNA plasmids and
FuGENE transfection reagent (Promega E2312) were formed
and applied to cells dropwise. Complete medium was added
back to the cells 6–8 hours post-transfection. In microarray RT-
PCR validation experiments, 1.5 mg of pSUPuro constructs were
dosed per transfection, and continuous puromycin selection
(final concentration 2.25 mg/ml) followed till harvest.
Animal breeding and tissue dissection
The severe SMA mouse model (mSmn -/-; hSMN2 C/C)
(Jackson Laboratory 005024);45 which generally survives 6–8 d
Table 4. Summary of SMA-associated splicing changes identiﬁed in multiple studies.
Study this paper Ref. 43 Ref. 39 Ref. 39 Ref. 38 Ref. 39 
Model severe Δ7 Δ7 Δ7 Δ7 Δ7 
stage P3 P1 P1 P7 P11 P13 
samples motoneurons motoneurons spinal cord spinal cord spinal cord spinal cord 
method EJA NGS EA EA EA EA 
this paper   3 2 1 2 0 
Ref. 43, P1 3   0 0 1 0 
Ref. 39, P1 2 0   4 1 2 
Ref. 39, P7 1 0 4   5 13 
Ref. 38, P11 2 1 1 5   13 
Ref. 39, P13 0 0 2 13 13   
A clustering of matches between this paper and Ref. 43 as well as between the studies of Refs 38 and 39 is indicated by grey shading and
stronger cell separations. EJA, exon junction array; NGS, next generation sequencing; EA, exon array.
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was used in this study. New born mice were genotyped44 on the
day of birth (P0), and dissection was carried out at P3. Spinal
cords were harvested from mice of either SMA (mSmn ¡/¡;
hSMN2C/C) or carrier (mSmn C/¡; hSMN2C/C) genotype.
Additionally, we used SMA animals with multiple copies of a
U7-ESE-B1 transgene that partly corrects the splicing of SMN2
exon 7 and suppresses the SMA phenotype (mSmn ¡/¡;
hSMN2C/C; U7-ESE-B1).44 The animals were kept at the cen-
tral animal house of Insel hospital and handled according to
Swiss animal protection law under the permissions BE 102/06,
BE 5/10 and BE 14/13.
Laser capture micro-dissection (LCM), exon junction
microarray and data mining
The lumbar region of the spinal cord was isolated and embed-
ded in O.C.T compound for storage at ¡80C. To prepare for
LCM, the embedded sample was cut into 30 mm slices in a cryostat
and transferred onto membrane slides (MMI 50102). Samples
were stained with methylene blue (Sigma 03978), and subsequently
destained/dehydrated in absolute ethanol. MMI CellCut (Molecu-
lar Machines & Industries, Glattbrugg, Switzerland) and PALM
Microbeam (Zeiss) LCM systems were used to collect the MN
samples for microarray hybridization and validation, respectively.
MN cell bodies were collected rapidly in LCM isolation caps
(MMI 50202) and immediately stabilised in the Picopure RNA
isolation kit extraction buffer (AppliedBiosystems KIT0204).
The RNA extraction was performed with the Picopure RNA
isolation kit, and samples were subjected to on-column DNase
treatment. The quality and integrity of obtained RNA was then
analyzed with a 2100 Bioanalyser (Agilent). Only RNAs with
clearly visible large rRNA bands were used. The RNA input was
standardised before reverse transcription (RT) and cDNA ampli-
fication with Oviation Pico WTA system (Nugen 3300) kits or
the later version V2 (Nugen 3302).
Affymetrix exon-junction microarray chips and MN samples
were processed at the Friedrich Miescher Institute functional
genomic facility where RNA isolation, quantification, cDNA
amplification and chip hybridization were carried out. The
scanned chip images were analyzed by M.K. in the lab of J.U. at
the MRC-LMB in Cambridge. The analysis of microarray data
was done with ASPIRE version 3 (Analysis of SPlicing Isoform
REciprocity) software as described earlier.48 ASPIRE3 predicts
splicing changes from reciprocal probe sets that recognize either
inclusion or skipping of an alternative exon. Background sub-
traction and ranking of predicted splicing changes are done dur-
ing the analysis. The original CEL files have been deposited in
the ArrayExpress database at EBI (http://www.ebi.ac.uk/arrayex
press/; accession number E-MTAB-3170).
RNA extraction
Total RNA from cultured cells was extracted with homemade
Tri-Reagent75 and resuspended in diethyl pyrocarbonate-treated
water. Mouse tissues samples were either chopped into small
pieces or snap frozen, and then crushed with a pestle (BioCon-
cept 100539). The RNA was then extracted with an RNeasy
mini kit (Qiagen 74104). All isolated RNA samples were
subjected to DNase I treatment (Roche 04716728001). The
RNA quantity and integrity were checked by Nanodrop 2000
spectrophotometer and gel electrophoresis, respectively. Only
RNAs with clearly visible large rRNA bands were used and RNA
inputs were standardised for RT-PCR analyses.
Splicing analysis by RT-PCR and band sequencing
The Ensembl (Archive site Feb 2011) and Aceview databases
were used to study the region of interest corresponding to micro-
array probes. Based on these informations, primers were designed
and checked for specificity by BLAST (http://www.ncbi.nlm.nih.
gov/tools/primer-blast/). Primers were purchased from Micro-
synth (Balgach, Switzerland). Primers specific for 5.8S rRNA and
for mouse SMN mRNA were used to control equal inputs and
SMN depletion, respectively.
For reverse transcription (RT), 3 mg of isolated RNA was
incubated with reverse transcriptase (Agilent 60010951), and
both oligo dT and random primers were included in the reac-
tions. The RT reactions were performed at 42C for 1 hour, and
the enzyme was inactivated at 85C.
PCR reactions were performed on an Eppendorf mastercycler.
The cycles generally consisted of denaturation at 95C and
annealing at 55C (or at an optimised temperature as tested by
gradient PCR) in Faststart PCR mastermix (Roche
04710444001). The numbers of PCR cycles were adjusted
according to the abundance of transcripts detected in the various
samples. To clone and sequence individual PCR products, ampli-
fications (20 cycles) were carried out with PfuUltra High-Fidelity
DNA polymerase (Agilent 600387), DNA bands of interest were
excised from agarose gels, purified and cloned into pGEM-T
Easy vector (Promega A1360). Mini-prep DNA was sequenced
through either an in-house sequencing service (Appliedbiosys-
tems ABI 3100) or by Microsynth (Balgach, Switzerland).
Real-time quantitative RT-PCR analysis
The real-time quantitative RT-PCR experiments were per-
formed by following the minimum information for publication of
quantitative real-time PCR experiment (MIQE) guidelines.76 The
reactions were analyzed on a Rotor-Gene Q real-time PCR cycler
(Qiagen). Each PCR program performed 40 cycles of amplifica-
tion, consisting of a 15 sec denaturing step at 95C, 15 sec anneal-
ing at 60C, and 20 sec extension at 72C. The recording range of
the melting curve was set from 70C to 95C. For each experi-
mental variant, several independent experiments were performed,
and all samples were measured in duplicates. Based on a list of
coding and non-coding77 genes, additional data from the literature
and our own initial experiments, we selected the non-coding 7SK
RNA as the most suitable reference gene to normalize the qPCR
data. After normalization for this reference, DDCT values and fold
changes of the measured RNAs were calculated.
Western blots and antibodies
Cells were lysed in home-made RIPA buffer [150 mM NaCl,
0.1%NP-40, 0.5% sodium deoxycholate, 50mMTris (pHD 8 .0)]
supplemented with protease inhibitor cocktail (Calbiochem
539134) and 1mM DTT. The lysates were subjected to Dounce
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homogenization on ice, and the soluble fraction was obtained by
12,000g centrifugation, aliquoted and snap frozen. The protein con-
centration of samples was determined by BCA protein assay kit
(Pierce 23225).
Soluble proteins were separated on 10% SDS-polyacrylamide
gels and transferred onto Immobilon-FL PVDF membrane (Milli-
pore IPFL00010). A solution of 5% milk powder was applied to
the membranes as blocking solution for 1 hour at room tempera-
ture. Blots were incubated with primary antibodies at 4C over-
night. Rabbit antibody against mouse Smn44 and mouse anti-a
tubulin antibody (developmental studies hybridoma bank AA 4.3-
s) were diluted 1:1’000 and 1:4’000, respectively. Both secondary
antibodies donkey anti-mouse 800cw (Odyssey IRDye 92632212)
and donkey anti-rabbit 680 (Odyssey IRDye 92632221) were
used at a dilution factor of 1:10’000, and their co-incubations
with blots were performed in the dark. TBST buffer (10 nM Tris,
pH 7.5, 150 mM NaCl, 0.05% Tween 20) was used for interval
washes. An Odyssey infrared imaging system (Licor) was used to
scan blot membranes and quantify proteins of interest.
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